Exploring new approaches to targeting cancer
Update on the T cell engager niche with an emerging agent of interest
Continuing our ongoing series on immunosuppression and finding ways to overcome the hostile TME
Who's going to the masquerade ball and how might they fare in the future?
Hidden early stage gems to watch out for at ASCO21
New developments on the KRAS and SHP2 front
New research is emerging which may have an impact on future trial designs as well as combination partners and even different tumour types.
Bridging the DDR gap from AACR to ASCO
Who's going to win in the battle between protein degraders and small molecule inhibitors?
What can we learn from C4 Therapeutics monoDAC, CFT7455?
A look at the subtleties and nuances under the hood of the Arvinas PROTACs
13 ways in which CAR based or gene therapies can improve on current approaches to cell therapies
A look at new data in the Menin/MLLr inhibitor landscape in acute leukemias
A look at switchable CAR-T cell therapies, plus CARs based on alternative immune cells.
13 talks at AACR21 caught our attention - which ones intrigued or dismayed - and why?
A rock around the bispecific clock highlighting key presentations coming at the AACR 2021 virtual meeting
What's hot in early preclinical development to watch out for?
A look at a potential emerging target which could be druggable
What's hot on the DDR front and PARP inhibitor space at AACR21?
Noteworthy AACR21 on-demand presentations.
Emerging areas in cool new science around targeted therapies
Combinations will be the future for KRAS inhibitors but which ones and why? Includes some new ideas!
Capturing attention in the crowded protein degradation niche
What to watch out for in the protein degradation niche
